GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,555 | 5,297 | 350 | 851 | 5 |
| TOTAL | $27,643 | $5,661 | $833 | $971 | $188 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 0 | 84 | 92 | 107 |
| TOTAL | $N/A | $N/A | $84 | $92 | $107 |
| Total Assets | $27,643 | $5,661 | $917 | $1,063 | $295 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 26,303 | 23,000 | 21,844 | 13,257 |
| Accounts payable and accrued liabilities | 2,377 | 2,243 | 2,171 | 2,001 | 2,370 |
| Accrued Expenses | 856 | 6,134 | 5,410 | 4,596 | 5,387 |
| Other current liabilities | 362 | 383 | N/A | N/A | N/A |
| TOTAL | $3,626 | $35,094 | $30,694 | $28,562 | $21,150 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $3,626 | $35,094 | $30,694 | $28,562 | $21,150 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 704 | 946 | 153 | 150 | 138 |
| Common Shares | 25,977 | 5 | 78 | 75 | 71 |
| Retained earnings | -625,079 | -595,797 | -580,695 | -577,819 | -569,040 |
| Other shareholders' equity | -168 | 3 | -144 | -144 | -166 |
| TOTAL | $24,017 | $-29,433 | $-29,777 | $-27,499 | $-20,855 |
| Total Liabilities And Equity | $27,643 | $5,661 | $917 | $1,063 | $295 |